Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Geisinger Medical Oncology-Lewisburg
1137
mi
from
Lewisburg, PA
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Geisinger Medical Oncology-Lewisburg
1137
mi
from
Lewisburg, PA
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Geisinger Wyoming Valley/Henry Cancer Center
1195
mi
from
Wilkes-Barre, PA
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Geisinger Wyoming Valley/Henry Cancer Center
1195
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
University of Vermont College of Medicine
1356
mi
from
Burlington, VT
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
University of Vermont College of Medicine
1356
mi
from
Burlington, VT
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Hawaii Oncology Inc-Pali Momi
3718
mi
from
'Aiea, HI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Hawaii Oncology Inc-Pali Momi
3718
mi
from
'Aiea, HI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Pali Momi Medical Center
3719
mi
from
'Aiea, HI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Pali Momi Medical Center
3719
mi
from
'Aiea, HI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Hawaii Cancer Care Inc-POB II
3717
mi
from
Honolulu, HI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Hawaii Cancer Care Inc-POB II
3717
mi
from
Honolulu, HI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Hawaii Cancer Care Inc-Liliha
3716
mi
from
Honolulu, HI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Hawaii Cancer Care Inc-Liliha
3716
mi
from
Honolulu, HI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Hawaii Oncology Inc-Kuakini
3715
mi
from
Honolulu, HI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Hawaii Oncology Inc-Kuakini
3715
mi
from
Honolulu, HI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Reid Health
710
mi
from
Richmond, IN
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Reid Health
710
mi
from
Richmond, IN
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Cancer Center of Kansas, PA - Wichita
27
mi
from
Wichita, KA
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Cancer Center of Kansas, PA - Wichita
27
mi
from
Wichita, KA
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Saint Vincent Frontier Cancer Center
780
mi
from
Billings, MT
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Saint Vincent Frontier Cancer Center
780
mi
from
Billings, MT
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Memorial Sloan Kettering at Basking Ridge
1258
mi
from
Basking Ridge, NJ
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Memorial Sloan Kettering at Basking Ridge
1258
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Memorial Sloan Kettering Commack
1324
mi
from
Commack, NY
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Memorial Sloan Kettering Commack
1324
mi
from
Commack, NY
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Memorial Sloan Kettering Rockville Centre
1305
mi
from
Rockville Centre, NY
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Memorial Sloan Kettering Rockville Centre
1305
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Memorial Sloan Kettering Sleepy Hollow
1295
mi
from
Sleepy Hollow, NY
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Memorial Sloan Kettering Sleepy Hollow
1295
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Sanford Broadway Medical Center
633
mi
from
Fargo, ND
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Sanford Broadway Medical Center
633
mi
from
Fargo, ND
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Wright-Patterson Medical Center
755
mi
from
Wright-Patterson Air Force Base, OH
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Wright-Patterson Medical Center
755
mi
from
Wright-Patterson Air Force Base, OH
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Saint Vincent Hospital Cancer Center Green Bay
690
mi
from
Green Bay, WI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Saint Vincent Hospital Cancer Center Green Bay
690
mi
from
Green Bay, WI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Saint Vincent Hospital Cancer Center at Saint Mary's
689
mi
from
Green Bay, WI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Saint Vincent Hospital Cancer Center at Saint Mary's
689
mi
from
Green Bay, WI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
HSHS Saint Nicholas Hospital
670
mi
from
Sheboygan, WI
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
HSHS Saint Nicholas Hospital
670
mi
from
Sheboygan, WI
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
MedStar Washington Hospital Center
1127
mi
from
Washington,
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
MedStar Washington Hospital Center
1127
mi
from
Washington,
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Central Vermont Medical Center/National Life Cancer Treatment
1383
mi
from
Berlin, VT
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Central Vermont Medical Center/National Life Cancer Treatment
1383
mi
from
Berlin, VT
Click here to add this to my saved trials
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Phase I Study of Infusion of Umbilical Cord Blood (UCB) Derived CD25+CD4+ T-Regulatory (Treg) Cells After Nonmyeloablative Cord Blood Transplantation
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Phase I Study of Infusion of Umbilical Cord Blood (UCB) Derived CD25+CD4+ T-Regulatory (Treg) Cells After Nonmyeloablative Cord Blood Transplantation
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer
Intraoperative NIR-Guided Sentinel Lymph Node Mapping in Esophageal Cancer
Status: Enrolling
Updated:  11/29/2017
Brigham and Women's Hosp
1444
mi
from
Boston, MA
NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer
Intraoperative NIR-Guided Sentinel Lymph Node Mapping in Esophageal Cancer
Status: Enrolling
Updated: 11/29/2017
Brigham and Women's Hosp
1444
mi
from
Boston, MA
Click here to add this to my saved trials
NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer
Intraoperative NIR-Guided Sentinel Lymph Node Mapping in Esophageal Cancer
Status: Enrolling
Updated:  11/29/2017
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer
Intraoperative NIR-Guided Sentinel Lymph Node Mapping in Esophageal Cancer
Status: Enrolling
Updated: 11/29/2017
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
Status: Enrolling
Updated:  11/29/2017
Mayo Clinic Arizona
835
mi
from
Scottsdale, AZ
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
Status: Enrolling
Updated: 11/29/2017
Mayo Clinic Arizona
835
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Phase I/II Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated:  11/29/2017
Fox Chase Cancer Center
1229
mi
from
Philadelphia, PA
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Phase I/II Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Status: Enrolling
Updated: 11/29/2017
Fox Chase Cancer Center
1229
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
A Phase II Trial of Short-Term Everolimus (RAD001) to Predict Response in Women With Operable Breast Cancer
Status: Enrolling
Updated:  11/29/2017
University of Minnesota Children's Hospital - Fairview
552
mi
from
Minneapolis, MN
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
A Phase II Trial of Short-Term Everolimus (RAD001) to Predict Response in Women With Operable Breast Cancer
Status: Enrolling
Updated: 11/29/2017
University of Minnesota Children's Hospital - Fairview
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Empowering Cancer Survivors Through Information Technology
Empowering Cancer Survivors Through Information Technology
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Empowering Cancer Survivors Through Information Technology
Empowering Cancer Survivors Through Information Technology
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer
A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer
Status: Enrolling
Updated:  11/29/2017
University of Minnesota Cancer Center
552
mi
from
Minneapolis, MN
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer
A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer
Status: Enrolling
Updated: 11/29/2017
University of Minnesota Cancer Center
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Tissue Sample Collection From Patients With Fanconi Anemia
Fanconi Anemia Cancer Cell Repository
Status: Enrolling
Updated:  11/30/2017
Knight Cancer Institute at Oregon Health and Science University
1383
mi
from
Portland, OR
Tissue Sample Collection From Patients With Fanconi Anemia
Fanconi Anemia Cancer Cell Repository
Status: Enrolling
Updated: 11/30/2017
Knight Cancer Institute at Oregon Health and Science University
1383
mi
from
Portland, OR
Click here to add this to my saved trials
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness.
Status: Enrolling
Updated:  11/30/2017
University of Connecticut Health Center
1350
mi
from
Farmington, CT
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness.
Status: Enrolling
Updated: 11/30/2017
University of Connecticut Health Center
1350
mi
from
Farmington, CT
Click here to add this to my saved trials
Patient Satisfaction With Propofol for Out Patient Colonoscopy
Patient Satisfaction With Propofol for Out Patient Colonoscopy: A Prospective, Randomized, Double-Blind Study
Status: Enrolling
Updated:  11/30/2017
Mount Carmel Health System
817
mi
from
Columbus, OH
Patient Satisfaction With Propofol for Out Patient Colonoscopy
Patient Satisfaction With Propofol for Out Patient Colonoscopy: A Prospective, Randomized, Double-Blind Study
Status: Enrolling
Updated: 11/30/2017
Mount Carmel Health System
817
mi
from
Columbus, OH
Click here to add this to my saved trials
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
A Randomized Phase II Study of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/30/2017
Ohio State University
810
mi
from
Columbus, OH
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
A Randomized Phase II Study of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/30/2017
Ohio State University
810
mi
from
Columbus, OH
Click here to add this to my saved trials
Colonoscope Insertion Trial Protocol
Study to Examine Insertion of 2 Colonoscopes Trial
Status: Enrolling
Updated:  11/30/2017
University of Connecticut Health Center
1350
mi
from
Farmington, CT
Colonoscope Insertion Trial Protocol
Study to Examine Insertion of 2 Colonoscopes Trial
Status: Enrolling
Updated: 11/30/2017
University of Connecticut Health Center
1350
mi
from
Farmington, CT
Click here to add this to my saved trials
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma
Status: Enrolling
Updated:  11/30/2017
University of Arizona Health Sciences Center
835
mi
from
Tucson, AZ
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma
Status: Enrolling
Updated: 11/30/2017
University of Arizona Health Sciences Center
835
mi
from
Tucson, AZ
Click here to add this to my saved trials
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma
Status: Enrolling
Updated:  11/30/2017
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma
Status: Enrolling
Updated: 11/30/2017
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
Measurement of Ca Kinetics in Humans With Prostate Cancer-induced Bone Disease
Status: Enrolling
Updated:  12/1/2017
Lawrence Livermore National Laboratory
1302
mi
from
Livermore, CA
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
Measurement of Ca Kinetics in Humans With Prostate Cancer-induced Bone Disease
Status: Enrolling
Updated: 12/1/2017
Lawrence Livermore National Laboratory
1302
mi
from
Livermore, CA
Click here to add this to my saved trials
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome.
Status: Enrolling
Updated:  12/1/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
1410
mi
from
Seattle, WA
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome.
Status: Enrolling
Updated: 12/1/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Post Transplant Donor Lymphocyte Infusion
Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Post Transplant Donor Lymphocyte Infusion
Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Stem Cell Transplantation for Hematological Malignancies
Busulfan, Cyclophosphamide, and Melphalan Followed by Allogeneic Hematopoietic Cell Transplantation in Patients With Hematological Malignancies
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Stem Cell Transplantation for Hematological Malignancies
Busulfan, Cyclophosphamide, and Melphalan Followed by Allogeneic Hematopoietic Cell Transplantation in Patients With Hematological Malignancies
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
Phase II Study of Naltrexone for the Treatment of Hormone-Refractory, Metastatic Breast Cancer
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
Phase II Study of Naltrexone for the Treatment of Hormone-Refractory, Metastatic Breast Cancer
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
Phase II Study of Biweekly Carboplatin and Gemcitabine With Bevacizumab as 1st Line Treatment in Patients With Advanced, Inoperable Stage IIIb/IV NSCLC
Status: Enrolling
Updated:  12/3/2017
Hubert H. Humphrey Cancer Center
553
mi
from
Minneapolis, MN
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
Phase II Study of Biweekly Carboplatin and Gemcitabine With Bevacizumab as 1st Line Treatment in Patients With Advanced, Inoperable Stage IIIb/IV NSCLC
Status: Enrolling
Updated: 12/3/2017
Hubert H. Humphrey Cancer Center
553
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
Phase II Study of Biweekly Carboplatin and Gemcitabine With Bevacizumab as 1st Line Treatment in Patients With Advanced, Inoperable Stage IIIb/IV NSCLC
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Cancer Center
552
mi
from
Minneapolis, MN
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
Phase II Study of Biweekly Carboplatin and Gemcitabine With Bevacizumab as 1st Line Treatment in Patients With Advanced, Inoperable Stage IIIb/IV NSCLC
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Cancer Center
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Conditioning for Graft Failure After Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Conditioning for Graft Failure After Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
MT2004-30: Tomotherapy for Solid Tumors
Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
MT2004-30: Tomotherapy for Solid Tumors
Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase I/II Trial of Lenalidomide in Combination With Liposomal Doxorubicin for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Medical Center, Fairview
552
mi
from
Minneapolis, MN
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase I/II Trial of Lenalidomide in Combination With Liposomal Doxorubicin for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Medical Center, Fairview
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
A Phase I/II Study of Combination of Gemcitabine, Oxaliplatin and Sorafenib (GEMOX-Sorafenib) in Patients With Advanced Biliary Tract Cancer
Status: Enrolling
Updated:  12/3/2017
University of Miami
1319
mi
from
Miami, FL
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
A Phase I/II Study of Combination of Gemcitabine, Oxaliplatin and Sorafenib (GEMOX-Sorafenib) in Patients With Advanced Biliary Tract Cancer
Status: Enrolling
Updated: 12/3/2017
University of Miami
1319
mi
from
Miami, FL
Click here to add this to my saved trials
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
MT2008-15: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Nonmyeloablative Preparative Regimen and Priming With Complement 3a Fragment (C3a)
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Medical Center, Fairview
552
mi
from
Minneapolis, MN
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
MT2008-15: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Nonmyeloablative Preparative Regimen and Priming With Complement 3a Fragment (C3a)
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Medical Center, Fairview
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials